Table 3 Multivariable HRs (95% CI) for the association of total (pre- and post-diagnostic) and post-diagnostic duration of aspirin use and post-diagnostic frequency aspirin use with breast cancer-specific mortality and total mortality in the Nurses’ Health Studies

From: Regular aspirin use, breast tumor characteristics and long-term breast cancer survival

	Breast cancer mortality				Total mortality
	Total duration of aspirin use				Total duration of aspirin use
Overall	Nonuser	<5 years	≥5 years	p-trend	Nonuser	<5 years	≥5 years	p-trend
No. of events	721	46	273		1363	73	802
Person years	60,184	5507	41,777		60,184	5507	41,777
Age- and pre-diagnostic aspirin-adjusted	1.0 (ref)	0.67 (0.50, 0.91)	0.50 (0.43, 0.58)	<0.0001	1.0 (ref)	0.79 (0.63, 1.01)	0.61 (0.56, 0.67)	<0.0001
Multivariable^a adjusted	1.0 (ref)	0.73 (0.54, 0.99)	0.61 (0.52, 0.71)	<0.0001	1.0 (ref)	0.87 (0.68, 1.10)	0.70 (0.63, 0.77)	<0.0001
	Post-diagnostic duration of aspirin use				Post-diagnostic duration of aspirin use
Overall	Nonuser	<5 years	≥5 years	p-trend	Nonuser	<5 years	≥5 years	p-trend
No. of events	721	159	160		1363	273	602
Person years	60,184	18,679	28,605		60,184	18,679	28,605
Age- and pre-diagnostic aspirin-adjusted	1.0 (ref)	0.59 (0.49, 0.71)	0.47 (0.39, 0.57)	<0.0001	1.0 (ref)	0.66 (0.57, 0.76)	0.61 (0.55, 0.68)	<0.0001
Multivariable^a adjusted	1.0 (ref)	0.71 (0.58, 0.86)	0.56 (0.46, 0.67)	<0.0001	1.0 (ref)	0.74 (0.63, 0.85)	0.70 (0.63, 0.78)	<0.0001
	No. of aspirin tablets per week				No. of aspirin tablets per week
Overall	Nonuser	0.5–5 tabs/week	≥6 tabs/week	p-trend	Nonuser	0.5–5 tabs/week	≥6 tabs/week	p-trend
No. of events	811	276	101		1619	772	259
Person years	69,413	44,685	11,671		69,413	44,685	11,671
Age- and pre-diagnostic aspirin-adjusted	1.0 (ref)	0.51 (0.44, 0.58)	0.62 (0.50, 0.77)	<0.0001	1.0 (ref)	0.59 (0.54, 0.64)	0.78 (0.68, 0.89)	<0.0001
Multivariable^a adjusted	1.0 (ref)	0.61 (0.53, 0.70)	0.59 (0.48, 0.74)	<0.0001	1.0 (ref)	0.70 (0.64, 0.76)	0.73 (0.63, 0.83)	<0.0001

^aMultivariable model adjusted for age at diagnosis (continuous), calendar year of diagnosis (continuous), pre-diagnostic aspirin use (never, past, current, missing), stage (I, II, III), chemotherapy (yes, no, missing), hormone therapy (yes, no, missing), radiotherapy (yes, no, missing), pre-diagnostic BMI (normal weight, overweight, obese, missing), change in BMI from pre- to post-diagnosis (>2 kg/m², ≤2 and >−0.5 kg/m², ≤−0.5 kg/m², missing), post-diagnostic physical activity (by quartile, missing), post-diagnostic smoking (current, past, never, missing), neighborhood socioeconomic status (nSES) (by quartile, missing), pre-diagnostic oral contraceptive use (ever, never, missing), pre-diagnostic menopausal hormone replacement therapy use (ever, never, missing), parity (parous, non-parous/unknown), menopausal status prior to diagnosis (premenopausal, postmenopausal, unknown), estrogen receptor status (positive, negative, missing), and propensity score. Propensity score was calculated by estimating the probability of regular use of aspirin based on age (continuous), BMI (normal weight, overweight, obese, unknown), physical activity (by quartile, missing), neighborhood socioeconomic status (nSES) (by quartile, missing), history of angina (yes, no), history of myocardial infarction (yes, no), history of stroke (yes, no), history of rheumatoid arthritis (yes, no).

Back to article page

Table 3 Multivariable HRs (95% CI) for the association of total (pre- and post-diagnostic) and post-diagnostic duration of aspirin use and post-diagnostic frequency aspirin use with breast cancer-specific mortality and total mortality in the Nurses’ Health Studies

Search

Quick links